William Blair Weighs in on Pyxis Oncology, Inc.’s Q3 2024 Earnings (NASDAQ:PYXS)

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Investment analysts at William Blair upped their Q3 2024 earnings per share estimates for Pyxis Oncology in a note issued to investors on Wednesday, August 14th. William Blair analyst A. Hsieh now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their prior forecast of ($0.35). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. William Blair also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.28) EPS and FY2026 earnings at ($1.28) EPS.

Several other brokerages also recently issued reports on PYXS. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Friday, August 16th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $10.00 price target on shares of Pyxis Oncology in a report on Tuesday, May 7th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $3.55 on Monday. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85. The business has a 50 day simple moving average of $3.39 and a 200 day simple moving average of $4.22. The stock has a market cap of $209.05 million, a price-to-earnings ratio of -2.61 and a beta of 1.29.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Fullcircle Wealth LLC bought a new position in Pyxis Oncology in the second quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology during the first quarter worth $59,000. The Manufacturers Life Insurance Company bought a new stake in Pyxis Oncology during the second quarter worth $65,000. Schulhoff & Co. Inc. lifted its stake in Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after acquiring an additional 20,000 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of Pyxis Oncology by 56.0% in the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after acquiring an additional 20,901 shares during the period. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.